Your NAD Levels Went Up.
Did Your Health Improve?

Why the biology attracted attention

Nicotinamide adenine dinucleotide is involved in energy metabolism and serves as a substrate for enzymes involved in cellular maintenance. NR, or nicotinamide riboside, and NMN, or nicotinamide mononucleotide, are precursors used in NAD biosynthesis. They are related interventions, not interchangeable names for the same product.^[1][2][3]

In a long-term mouse experiment, NMN improved several age-associated physiological measures, including aspects of energy metabolism and insulin sensitivity. Those findings helped justify human testing. They did not establish that supplementing a healthy human would extend life. An animal model can identify a plausible pathway while leaving the size, durability and clinical relevance of the human effect unresolved.^[1]

A blood result is not a whole-body readout

Consider a crossover trial in 12 older men given oral NR, 1 g daily, for 21 days. Whole-blood NAD was 47.75 μM during NR versus 20.90 μM during placebo. Muscle NAD-related metabolites changed, but muscle NAD+ itself did not significantly increase. Mitochondrial bioenergetics and handgrip did not improve.^[2]

This is why “boosted the NAD metabolome” requires careful reading. It may refer to precursors, breakdown products or a sample compartment rather than a uniform rise in NAD inside all cells. A striking blood result is evidence of biological exposure; it cannot substitute for a muscle-performance test. Read the aged-muscle study card.

A positive signal in peripheral artery disease

The NICE trial randomized 90 people with peripheral artery disease to NR, NR plus resveratrol, or placebo for six months. The tested NR exposure was 1,000 mg daily; the combination added 125 mg resveratrol. Six-minute walking distance favored NR alone by 17.6 metres over placebo.^[6]

This is a functional finding in people with impaired circulation, not proof of an endurance advantage in healthy athletes. Resveratrol did not add benefit. The modest sample and statistical threshold make replication important; the larger 31-m estimate from adherent participants was post hoc, not the primary randomized comparison. Diarrhea was reported in 39.3% with NR alone versus 27.6% with placebo.^[6][17]

Runners: thresholds are not VO₂max

A six-week study randomized 48 amateur runners to placebo or NMN at 300, 600 or 1,200 mg daily, alongside exercise training. Some ventilatory-threshold measures improved more at the medium and higher exposures, but VO₂max, peak power and body composition did not show corresponding benefits. No adverse events were reported.^[5]

That distinction matters. A change in the workload at which breathing patterns shift does not mean maximal aerobic capacity increased or race times improved. With 12 people per group, this is an interesting performance signal that needs a larger, longer replication. Read the runner study card.

Older adults: read the primary endpoint first

In 60 older adults, 250 mg NMN daily for 12 weeks increased blood NAD and favored selected walking and sleep measures. But the prespecified primary stepping test showed no significant between-group difference. No treatment-related adverse effects were reported in the abstract.^[7]

Read the walking and sleep study card. Secondary outcomes are not worthless. They simply answer a different evidentiary question, especially when many outcomes were tested.

The NMN trial in prediabetic women

Twenty-five postmenopausal women with overweight or obesity and prediabetes completed a 10-week randomized trial of 250 mg NMN daily or placebo. Insulin-stimulated glucose disposal increased by 25 ± 7% within the NMN group, with no corresponding change after placebo. The trial reported a significant group-by-time-by-condition interaction.^[3]

The metabolic-clamp result is biologically meaningful, but body composition and routine metabolic measures did not improve relative to placebo. No adverse events were reported. This small, selected population does not establish a general anti-obesity effect, and improved muscle insulin signaling should not be relabeled as muscle hypertrophy.^[3]

NR did not reproduce the same metabolic pattern

In a different trial, 40 sedentary men with obesity received NR at 1,000 mg twice daily or placebo for 12 weeks. NR did not improve insulin sensitivity, resting energy expenditure, lipid oxidation or body composition.^[4]

It would be tempting to conclude “NMN beats NR.” These were not head-to-head trials: sex, metabolic state, compound, exposure and study methods differed. The correct conclusion is narrower—one NMN trial found a specific metabolic benefit that a separate NR trial did not show. A comparative trial is needed to attribute that difference to the molecule.

Parkinson’s disease: a rationale worth pursuing

NADPARK randomized 30 newly diagnosed, untreated patients to 1,000 mg NR daily or placebo for 30 days. Brain NAD rose variably, with metabolic changes and mild clinical improvement associated with participants who showed an increase. NR was well tolerated.^[8]

A small phase I study can show that an intervention reaches its biological target. It cannot establish that Parkinson’s progression slows. The larger NOPARK registry was checked for this article; posted efficacy results were not located. Read the NADPARK card.^[16]

Cognition: the newer negative results matter

A 2026 randomized pilot in amnestic mild cognitive impairment provides a direct test of the article’s central question. Forty-two participants completed 12 weeks. Blood NAD doubled in the NR group, but the primary cognitive outcome did not improve; neither did total cerebral blood flow or blood pressure. Exploratory regional blood-flow signals should not be presented as demonstrated memory improvement.^[9]

Similarly, a 58-person long-COVID trial tested 2,000 mg NR daily with a placebo lead-in design. NAD rose approximately 2.6–3.1-fold after 5–10 weeks in the initial NR group, but between-group differences in cognition, fatigue, sleep and mood were not significant. Favorable post-hoc changes from baseline were exploratory, unadjusted for multiple testing, and complicated by substantial dropout.^[10]

A 2026 exercise result deserves attention, too

In Friedreich’s ataxia, 66 participants were randomized to NR, exercise, both, or control for 12 weeks. The NR exposure was weight-based, 300–900 mg daily. Combination therapy improved peak oxygen uptake versus control by 0.21 L/min (95% CI 0.05–0.36; adjusted P=.0299). NR alone did not show a significant advantage.^[11]

This is encouraging in a specific neurological disease. The combination-versus-control result does not, by itself, prove that NR adds benefit beyond exercise or establishes synergy. It also does not supply a performance forecast for healthy lifters. The comparison must match the claim.

“NAD therapy” can describe oral NR, oral NMN, oral formulations of NAD, intravenous NAD, intravenous NR or other injected preparations. Changing the compound and route changes the intervention. An oral precursor trial cannot establish the benefits of a wellness infusion.

What infusion studies actually tested

A 2019 pilot tracked metabolites during a six-hour, 750-mg NAD infusion: eight men received NAD and three saline. That design examined disposition and metabolism, not whether treatment improves fatigue, memory or longevity.^[12]

It would nevertheless be inaccurate to say direct NAD has no randomized human research. A single-centre trial in 180 people with ischemic cardiomyopathy tested 10 mg IV NAD daily for seven days alongside heart-failure treatment. At one month, mean left-ventricular ejection fraction was 45.44% versus 42.44% with placebo (P=.024). The six-month composite event result—14.6% versus 24.7%, P=.089—was not statistically significant.^[13]

That is a disease-specific cardiac finding at a particular exposure. It cannot validate a much larger wellness drip in healthy people or establish improved survival. The study was not powered to settle clinical-event differences.^[13]

Tolerability is part of the story

A 2026 retrospective comparison of commercial IV NAD and IV NR reported moderate-to-severe gastrointestinal symptoms, increased heart rate and chest pressure during NAD infusions. Symptoms resolved after infusion completion, but the observational design and short follow-up limit what it can establish. Its exploratory biomarker findings are not proof of rejuvenation.^[14]

New oral NAD formulations also need outcome testing. A 2026 five-day randomized trial of LNAD+ enrolled 60 adults, with 50 in the primary analysis. It demonstrated biochemical activity, but no secondary clinical, wellbeing or wearable endpoint survived multiplicity correction. Five days can inform early pharmacology; it cannot establish healthy aging.^[15]

The studies reviewed here support a real biological effect and several worthwhile therapeutic hypotheses. They do not establish longer human lifespan, broad rejuvenation or a reliable increase in everyday energy for healthy users. Nor does an unsuccessful short trial eliminate every possible benefit in a different condition.

The distinction is between a research hypothesis and a dependable expectation. A person with a specific metabolic or neurological disorder may respond differently from a healthy athlete. A blood biomarker may move before a functional outcome does—or move without that outcome ever improving. Both possibilities require testing.

Short-term tolerance is not lifetime safety

Several small oral trials reported good short-term tolerability. That is useful information, but the sample sizes and durations cannot exclude uncommon harms or establish the safety of years of use. Infusion tolerability must be evaluated separately. “No adverse events reported” in a brief trial should retain its exact scope.^{[3][5][7][8][14]}

How to read the next NAD headline

Start with the endpoint before looking at the percentage. Was it blood NAD, a metabolite, a functional test or a clinical event? Then ask whether the improvement exceeded placebo, whether it was primary or exploratory, and whether the tested population resembles the person the advertisement is addressing.

The most defensible position is interested but specific. NAD biology is a serious research area. The clearest benefits should be described at the level at which they were demonstrated, while broader anti-aging promises remain questions for future trials.